Cadrenal Therapeutics, Inc. (CVKD) to Raise $7 Million in IPO
Cadrenal Therapeutics, Inc. (CVKD) to Raise $7 Million in IPO
Cadrenal Therapeutics, Inc. (CVKD) is planning to raise $7 million in an initial public offering (IPO) on Friday, December 16th, IPO Scoop reports. The company will be issuing 1,400,000 shares at $5.00 per share.
腎腎上腺治療有限公司（CVKD）計劃在 12 月 16 日（星期五）的首次公開募股（IPO）中籌集 7 萬美元，IPO 獨家報導。該公司將以每股五點五元發行 1,40 萬股股份。
Cadrenal Therapeutics, Inc. has a market-cap of $55.6 million.
腎臟治療, 公司. 擁有 55.6 萬美元的市值.
Boustead Securities and Sutter Securities acted as the underwriters for the IPO.
寶德證券及薩特證券擔任首次公開招股的承銷商。
Cadrenal Therapeutics, Inc. provided the following description of their company for its IPO: "(Note: Cadrenal Therapeutics, Inc. added Sutter Securities as a joint book-runner with Boustead Securities (previously sole book-runner) in an S-1/A filing dated Dec. 8, 2022. Previously: Cadrenal Therapeutics cut the size of its IPO in an S-1/A filing dated Dec. 6, 2022, to 1.4 million shares – down from 2 million shares – at $5.00 each to raise $7.0 million. This downsizing represents a 30 percent cut in the deal's size, in terms of estimated IPO proceeds. The company is offering all 1.4 million shares in the IPO. (**Note: Selling stockholders have registered to offer 1.7 million shares (1,704,783 shares) of common stock to be sold pursuant to a separate resale prospectus. We will not receive any proceeds from the sale of the common stock to be sold by the Selling Stockholders.) We are focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. We secured the rights to tecarfarin on April 1, 2022, via an asset purchase agreement from HESP LLC, a wholly owned subsidiary of Horizon Technology Finance Corp., which in turn had bought tecarfarin and the other assets of Espero Biopharma, Inc. We intend to complete the clinical development of tecarfarin and seek FDA approval for the drug. We intend to initiate our pivotal Phase 3 clinical trial in the second half of 2023, subject to completion of this offering and funding from additional financings, which we believe will be our remaining pivotal trial based upon the latest feedback that the prior owner of tecarfarin had with FDA in 2019. We have licensed out the rights to tecarfarin for several Asian markets, including China, to Lee's Pharmaceutical Holdings Limited, an integrated research-driven and market-oriented biopharmaceutical publicly listed company based in Hong Kong with over 25 years' experience in the pharmaceutical industry in China. Lee's Pharmaceutical Holdings Limited is developing tecarfarin as an anti-thrombotic for patients with mechanical heart valves. In 2020 and 2021, Lee's Pharmaceutical Holdings Limited completed two Phase 1 studies in China and Hong Kong; the company is currently preparing for its Phase 2 trial. Note: Revenue (zero) and net loss figures are from the date of inception on Jan. 25, 2022, through June 30, 2022. (Note: Cadrenal Therapeutics, Inc. filed its S-1 on Sept. 22, 2022; it submitted a confidential filing on July 15, 2022.) ".
腎上腺治療股份有限公司為其首次公開募股提供了以下描述：「（注意：腎上腺治療有限公司）在 2022 年 12 月 8 日的 S-1/A 文件中添加了薩特證券作為博斯特證券（以前唯一的賬簿管理人）的聯席賬簿管理人。以前：腎臟治療學在 2022 年 12 月 6 日的 S-1/A 檔案中將其首次公開募股的規模削減至 140 萬股，從 2 百萬股股下降至每股 5.00 美元，以籌集 7.0 萬美元。就首次公開招股收益估計而言，這種縮小規模代表交易規模下降了 30％。該公司在首次公開招股中發行的全部 140 萬股股票。(** 註：出售股東已註冊根據單獨的轉售招股章程發售 170 萬股（1,704,783 股）普通股。我們將不會收到出售股東出售的普通股所得的任何收益。）我們專注於開發 tecarfarin，這是一種具有孤兒藥物指示症的新型療法，旨在預防全身血栓栓塞（血凝塊）的末期腎病患者或 ESRD，和心房顫動（不規則心跳）或 AFIB。我們通過 Horizon Technology 金融股份有限公司的全資子公司 HESP LLC 的資產購買協議獲得了替卡法林的權利，該公司又購買了四卡法林和埃斯佩羅生物製藥公司的其他資產，我們打算完成替卡法林的臨床開發，並尋求 FDA 批准該藥物。我們打算在 2023 年下半年啟動關鍵的 3 期臨床試驗，但要完成此項服務並獲得額外融資的資金，我們認為這些試驗將是我們剩下的關鍵性試驗，這些試驗根據 tecarfarin 先前所有者於 2019 年與 FDA 進行的最新反饋。李氏藥業控股有限公司已向多個亞洲市場（包括中國）授權替卡法林。李氏藥業控股有限公司是一家總部位於香港的綜合研究驅動和以市場為導向的上市生物製藥上市公司，在中國製藥行業擁有超過 25 年的經驗。李氏藥業控股有限公司正在開發四卡法林作為一種抗血栓用於機械性心臟瓣膜患者的抗血栓藥物。在 2020 年和 2021 年，李氏大藥廠控股有限公司在中國和香港完成了兩項第一期研究，目前正準備進行第二階段試驗。注意：收入（零）和淨虧損數字是從 2022 年 1 月 25 日成立之日起至 2022 年 6 月 30 日止。注意：腎腎上腺治療有限公司於 2022 年 9 月 22 日提交了 S-1；它於 2022 年 7 月 15 日提交了一份機密申請。）」。
Cadrenal Therapeutics, Inc. was founded in 2022 and has 4 employees. The company is located at 822 A1A North, Suite 320 Ponte Vedra, Florida 32082 and can be reached via phone at (904) 300-0701 or on the web at
腎臟治療有限公司成立於 2022 年，擁有 4 名員工。該公司位於 822 A1A 北，套房 320 蓬特韋德拉，佛羅里達州 32082，可以通過電話聯繫到（904）300-0701 或在網絡上
Receive News & Ratings for Cadrenal Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收腎臟治療藥物公司的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Cad肾治療 Inc. 和相關公司的最新新聞和分析師評級的簡要每日摘要。